FDA Must Recognize Ephedra Ruling’s Nationwide Implications – Emord
This article was originally published in The Tan Sheet
Executive Summary
A Utah court ruling lifting an FDA ban on low-dose ephedra applies nationwide and cannot be interpreted by the agency as pertaining only to the district where the decision was issued, according to Jonathan Emord of the Washington, D.C. law firm Emord & Associates
You may also be interested in...
FDA Must Clarify Ephedra Case Impact – Supplement Trade Groups
FDA needs to "act promptly to address issues raised" by the recent Utah federal court decision that challenged aspects of the agency's ban on ephedra, leading supplement trade groups state in a joint letter to the agency
Ephedra Ruling Does Not Preclude FDA Legal Action In New District – Lawyers
The recent court ruling overturning FDA's ephedra ban is unlikely to extend to higher-dose forms, according to food and drug law experts
Utah Court Overturns Ephedra Ban For Low-Dose Products
A Utah federal court has barred FDA from enforcing its ban on ephedra products containing 10 mg or less of ephedrine alkaloids per daily dose